Pengxia Qu, Shuang Yang, Yaowen Guo, Tiantao Jing, Wan Zhang, Yuanbin Li
{"title":"基于限制三次样条模型的甲状腺功能状态与血清尿酸水平的关系：一项横断面研究。","authors":"Pengxia Qu, Shuang Yang, Yaowen Guo, Tiantao Jing, Wan Zhang, Yuanbin Li","doi":"10.2147/RMHP.S536398","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To date, no comprehensive studies have examined the relationship between various thyroid function statuses and thyroid hormone levels with uric acid levels. This study aims to analyze the correlation between thyroid disease and hyperuricemia.</p><p><strong>Patients and methods: </strong>Data from individuals undergoing health screenings in the Taiyuan area were collected. The data were categorized by thyroid disease type, thyroid function indices (FT4, FT3, and TSH), and serum uric acid (SUA) levels, followed by statistical analysis.</p><p><strong>Results: </strong>The analysis indicated that the prevalence rates were as follows: clinical hyperthyroidism (CHyper) at 0.9%, subclinical hyperthyroidism (SCHyper) at 0.7%, clinical hypothyroidism (CHypo) at 0.8%, subclinical hypothyroidism (SCHypo) at 13.7%, and hyperuricemia at 16.9%. Further analysis revealed that the prevalence of hyperuricemia increased with higher FT4 and FT3 levels but decreased with lower TSH levels. However, logistic regression analysis showed that after adjusting for covariates, thyroid disease status, including CHyper, SCHyper, CHypo, and SCHypo, was not significantly correlated with hyperuricemia. Among the thyroid function indices, only FT4 had a statistically significant effect on the risk of hyperuricemia (OR 1.028, 95% CI 1.011-1.045). Additionally, the restricted cubic spline (RCS) was employed to assess the dose-response relationship between thyroid function indicators (FT4, FT3, and TSH) within the normal reference range and the risk of hyperuricemia. The FT4 level exhibited a positive relationship with the risk of hyperuricemia (nonlinear test χ<sup>2</sup> was 0.26, <i>P > 0.05</i>). When FT4 exceeded 16.85 pmol/L, higher levels of FT4 became a risk factor for hyperuricemia.</p><p><strong>Conclusion: </strong>Thyroid disease status does not significantly affect hyperuricemia. However, within the normal range, the FT4 level demonstrates a positive dose-response relationship with the risk of hyperuricemia.</p>","PeriodicalId":56009,"journal":{"name":"Risk Management and Healthcare Policy","volume":"18 ","pages":"3199-3208"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476191/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Relationship Between Thyroid Function Status and Serum Uric Acid Levels Based on a Restricted Cubic Spline Model: A Cross-Sectional Study.\",\"authors\":\"Pengxia Qu, Shuang Yang, Yaowen Guo, Tiantao Jing, Wan Zhang, Yuanbin Li\",\"doi\":\"10.2147/RMHP.S536398\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To date, no comprehensive studies have examined the relationship between various thyroid function statuses and thyroid hormone levels with uric acid levels. This study aims to analyze the correlation between thyroid disease and hyperuricemia.</p><p><strong>Patients and methods: </strong>Data from individuals undergoing health screenings in the Taiyuan area were collected. The data were categorized by thyroid disease type, thyroid function indices (FT4, FT3, and TSH), and serum uric acid (SUA) levels, followed by statistical analysis.</p><p><strong>Results: </strong>The analysis indicated that the prevalence rates were as follows: clinical hyperthyroidism (CHyper) at 0.9%, subclinical hyperthyroidism (SCHyper) at 0.7%, clinical hypothyroidism (CHypo) at 0.8%, subclinical hypothyroidism (SCHypo) at 13.7%, and hyperuricemia at 16.9%. Further analysis revealed that the prevalence of hyperuricemia increased with higher FT4 and FT3 levels but decreased with lower TSH levels. However, logistic regression analysis showed that after adjusting for covariates, thyroid disease status, including CHyper, SCHyper, CHypo, and SCHypo, was not significantly correlated with hyperuricemia. Among the thyroid function indices, only FT4 had a statistically significant effect on the risk of hyperuricemia (OR 1.028, 95% CI 1.011-1.045). Additionally, the restricted cubic spline (RCS) was employed to assess the dose-response relationship between thyroid function indicators (FT4, FT3, and TSH) within the normal reference range and the risk of hyperuricemia. The FT4 level exhibited a positive relationship with the risk of hyperuricemia (nonlinear test χ<sup>2</sup> was 0.26, <i>P > 0.05</i>). When FT4 exceeded 16.85 pmol/L, higher levels of FT4 became a risk factor for hyperuricemia.</p><p><strong>Conclusion: </strong>Thyroid disease status does not significantly affect hyperuricemia. However, within the normal range, the FT4 level demonstrates a positive dose-response relationship with the risk of hyperuricemia.</p>\",\"PeriodicalId\":56009,\"journal\":{\"name\":\"Risk Management and Healthcare Policy\",\"volume\":\"18 \",\"pages\":\"3199-3208\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476191/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Risk Management and Healthcare Policy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/RMHP.S536398\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Risk Management and Healthcare Policy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/RMHP.S536398","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
摘要
目的：到目前为止，还没有全面的研究检查各种甲状腺功能状态和甲状腺激素水平与尿酸水平之间的关系。本研究旨在分析甲状腺疾病与高尿酸血症的相关性。患者和方法：收集太原地区接受健康筛查的个体数据。根据甲状腺疾病类型、甲状腺功能指标（FT4、FT3、TSH）、血清尿酸（SUA）水平对数据进行分类，并进行统计学分析。结果：分析结果显示：临床甲状腺功能亢进（CHyper）患病率为0.9%，亚临床甲状腺功能亢进（SCHyper）患病率为0.7%，临床甲状腺功能减退（CHypo）患病率为0.8%，亚临床甲状腺功能减退（SCHypo）患病率为13.7%，高尿酸血症患病率为16.9%。进一步的分析显示，高尿酸血症的患病率随着FT4和FT3水平的升高而增加，但随着TSH水平的降低而降低。然而，逻辑回归分析显示，在调整协变量后，甲状腺疾病状态，包括CHyper、SCHyper、CHypo和SCHypo，与高尿酸血症无显著相关。甲状腺功能指标中，只有FT4对高尿酸血症风险有统计学意义（OR 1.028, 95% CI 1.011-1.045）。此外，采用限制性三次样条（RCS）评估正常参考范围内甲状腺功能指标（FT4、FT3和TSH）与高尿酸血症风险之间的剂量-反应关系。FT4水平与高尿酸血症风险呈正相关（非线性检验χ2为0.26,P < 0.05）。当FT4超过16.85 pmol/L时，较高的FT4水平成为高尿酸血症的危险因素。结论：甲状腺疾病状态对高尿酸血症无显著影响。然而，在正常范围内，FT4水平与高尿酸血症的风险呈正剂量反应关系。
The Relationship Between Thyroid Function Status and Serum Uric Acid Levels Based on a Restricted Cubic Spline Model: A Cross-Sectional Study.
Purpose: To date, no comprehensive studies have examined the relationship between various thyroid function statuses and thyroid hormone levels with uric acid levels. This study aims to analyze the correlation between thyroid disease and hyperuricemia.
Patients and methods: Data from individuals undergoing health screenings in the Taiyuan area were collected. The data were categorized by thyroid disease type, thyroid function indices (FT4, FT3, and TSH), and serum uric acid (SUA) levels, followed by statistical analysis.
Results: The analysis indicated that the prevalence rates were as follows: clinical hyperthyroidism (CHyper) at 0.9%, subclinical hyperthyroidism (SCHyper) at 0.7%, clinical hypothyroidism (CHypo) at 0.8%, subclinical hypothyroidism (SCHypo) at 13.7%, and hyperuricemia at 16.9%. Further analysis revealed that the prevalence of hyperuricemia increased with higher FT4 and FT3 levels but decreased with lower TSH levels. However, logistic regression analysis showed that after adjusting for covariates, thyroid disease status, including CHyper, SCHyper, CHypo, and SCHypo, was not significantly correlated with hyperuricemia. Among the thyroid function indices, only FT4 had a statistically significant effect on the risk of hyperuricemia (OR 1.028, 95% CI 1.011-1.045). Additionally, the restricted cubic spline (RCS) was employed to assess the dose-response relationship between thyroid function indicators (FT4, FT3, and TSH) within the normal reference range and the risk of hyperuricemia. The FT4 level exhibited a positive relationship with the risk of hyperuricemia (nonlinear test χ2 was 0.26, P > 0.05). When FT4 exceeded 16.85 pmol/L, higher levels of FT4 became a risk factor for hyperuricemia.
Conclusion: Thyroid disease status does not significantly affect hyperuricemia. However, within the normal range, the FT4 level demonstrates a positive dose-response relationship with the risk of hyperuricemia.
期刊介绍：
Risk Management and Healthcare Policy is an international, peer-reviewed, open access journal focusing on all aspects of public health, policy and preventative measures to promote good health and improve morbidity and mortality in the population. Specific topics covered in the journal include:
Public and community health
Policy and law
Preventative and predictive healthcare
Risk and hazard management
Epidemiology, detection and screening
Lifestyle and diet modification
Vaccination and disease transmission/modification programs
Health and safety and occupational health
Healthcare services provision
Health literacy and education
Advertising and promotion of health issues
Health economic evaluations and resource management
Risk Management and Healthcare Policy focuses on human interventional and observational research. The journal welcomes submitted papers covering original research, clinical and epidemiological studies, reviews and evaluations, guidelines, expert opinion and commentary, and extended reports. Case reports will only be considered if they make a valuable and original contribution to the literature. The journal does not accept study protocols, animal-based or cell line-based studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
